HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients ; volume:38 ; number:3 ; day:15 ; month:2 ; year:2021 ; pages:1690-1700 ; date:3.2021
Advances in therapy ; 38, Heft 3 (15.2.2021), 1690-1700, 3.2021
- Urheber
-
Morgan, Jake R.
Savinkina, Alexandra
Pires dos Santos, Ana Gabriela
Xue, Zhenyi
Shilton, Sonjelle
Linas, Benjamin
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-021-01647-4
- URN
-
urn:nbn:de:101:1-2021041814214384764805
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Morgan, Jake R.
- Savinkina, Alexandra
- Pires dos Santos, Ana Gabriela
- Xue, Zhenyi
- Shilton, Sonjelle
- Linas, Benjamin
- SpringerLink (Online service)
Ähnliche Objekte (12)
Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
Assessment of hepatic fibrosis, portal hemodynamic changes, and disease severity in patients with HCV-related liver cirrhosis after sustained virologic response to direct-acting antiviral drugs (DAAs)
Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination
Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy
Direct-acting antiviral therapy may help restore HCV-induced impaired redox balance and liver fibrosis process
Effect of direct-acting antiviral drugs on portal circulation hemodynamics in cirrhotic patients infected with HCV
Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices
Overreporting of adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs in the HERO study
Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
Role of abbreviated MRI protocol for screening of HCC in HCV related cirrhotic patients prior to direct-acting antiviral treatment
Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy
Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
Assessment of hepatic fibrosis, portal hemodynamic changes, and disease severity in patients with HCV-related liver cirrhosis after sustained virologic response to direct-acting antiviral drugs (DAAs)
Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination
Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy
Direct-acting antiviral therapy may help restore HCV-induced impaired redox balance and liver fibrosis process
Effect of direct-acting antiviral drugs on portal circulation hemodynamics in cirrhotic patients infected with HCV
Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices
Overreporting of adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs in the HERO study
Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
Role of abbreviated MRI protocol for screening of HCC in HCV related cirrhotic patients prior to direct-acting antiviral treatment
Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy
Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
Assessment of hepatic fibrosis, portal hemodynamic changes, and disease severity in patients with HCV-related liver cirrhosis after sustained virologic response to direct-acting antiviral drugs (DAAs)
Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination
Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy
Direct-acting antiviral therapy may help restore HCV-induced impaired redox balance and liver fibrosis process
Effect of direct-acting antiviral drugs on portal circulation hemodynamics in cirrhotic patients infected with HCV
Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices
Overreporting of adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs in the HERO study
Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
Role of abbreviated MRI protocol for screening of HCC in HCV related cirrhotic patients prior to direct-acting antiviral treatment